Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 40: 420-425, 1994;
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Frengen, J.
Right arrow Articles by Nustad, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Frengen, J.
Right arrow Articles by Nustad, K.

Clinical Chemistry, Vol 40, 420-425, Copyright © 1994 by American Association for Clinical Chemistry

Demonstration and minimization of serum interference in flow cytometric two-site immunoassays

J Frengen, B Kierulf, R Schmid, T Lindmo and K Nustad
Department of Physics, University of Trondheim-NTH, Norway.

The ability of serum factors to cross-link labeled mouse monoclonal antibody (mAb) of irrelevant specificity (mAb FN61, subclass IgG1) to different particle types coated with sheep IgG, bovine gamma-globulin, or mAb FN61 was measured simultaneously by flow cytometry. Significant interference with mAb FN61-coated particles was detected in 53 of 101 sera. Of the 30 sera showing the most pronounced interference, 23 were characterized by an even stronger cross-linking to particles coated with bovine gamma-globulin. These were designated type 1 sera. Seven sera, designated type 2, displayed a dominant interference with the mAb FN61-coated particles. The interference reaction in the two serum types was characterized by different kinetics, dependence on particle concentration, and response to blocking agents. The interference was minimized by addition of 500 micrograms of bovine gamma-globulin and 50 micrograms of mAb HH1 (IgG1) of irrelevant specificity per 10 microL of serum sample in a final assay volume of 100 microL.


The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
D. J. Warren, J. Bjerner, E. Paus, O. P. Bormer, and K. Nustad
Use of an In Vivo Biotinylated Single-Chain Antibody as Capture Reagent in an Immunometric Assay to Decrease the Incidence of Interference from Heterophilic Antibodies
Clin. Chem., May 1, 2005; 51(5): 830 - 838.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
J. Bjerner, O. P. Bormer, and K. Nustad
The War on Heterophilic Antibody Interference
Clin. Chem., January 1, 2005; 51(1): 9 - 11.
[Full Text] [PDF]

Home page
 Clin. Chem.Home page
J. Bjerner, K. Nustad, L. F. Norum, K. H. Olsen, and O. P. Bormer
Immunometric Assay Interference: Incidence and Prevention
Clin. Chem., April 1, 2002; 48(4): 613 - 621.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1994 by the American Association for Clinical Chemistry.